Sutro Biopharma Inc. has implemented a 1-for-10 reverse stock split, effective December 3, 2025, resulting in its common stock maintaining an average closing price of at least $1.00 and regaining compliance with Nasdaq's minimum bid price requirement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on December 17, 2025, and is solely responsible for the information contained therein.
Comments